Agrinews24 কৃষির সাথে, কৃষকের পাশে
Strategic sale accelerates vaccine innovation and access across Africa’s livestock sector.
AgriNews24.com: Phatisa, through Phatisa Food Fund 2 (“Phatisa”), has agreed to sell its interest in Deltamune (Pty) Ltd (“Deltamune”), a leading South Africa-based vaccine manufacturer, to Vaxxinova International B.V. (“Vaxxinova”), a global animal health company and part of the EW Group. The transaction expands Vaxxinova’s presence in Africa and affirms Phatisa’s strategy of delivering impact through operational excellence.
Established in 1995, Deltamune plays a trusted role in veterinary and public health, by developing and manufacturing vaccines used for production animals—particularly poultry—and expanding its reach to ruminants such as cattle and sheep.
Deltamune produces close to 15,000,000 vaccine doses annually and serves 12 countries across the SADC/COMESA region. Its portfolio includes:
- Registered vaccines – Commercial vaccines targeting diseases such as Avian Influenza, Coryza, Newcastle Disease, Salmonella, Anthrax, and Lumpy Skin Disease etc.
- Autogenous vaccines – Tailored animal vaccines designed for local African diseases and virus variants.
Victor van Solinge, Chief Executive Officer of Vaxxinova said: “We are excited to welcome Deltamune to the Vaxxinova group. This is a perfect cultural, strategic and operational fit where all stakeholders in and outside South Africa will benefit. In sub-Saharan Africa, the combined companies will offer an enriched portfolio of products and services. The now extended Vaxxinova group and its customers will benefit from exchange of technologies and expertise. We are grateful to Phatisa for allowing us to acquire Deltamune.
